Guardant Health (GH) Q1 Earnings Report Preview: What To Look For

Diagnostics company Guardant Health (NASDAQ:GH) will be reporting earnings tomorrow after market hours. Here’s what you need to know.

Guardant Health beat analysts’ revenue expectations by 4.8% last quarter, reporting revenues of $201.8 million, up 30.2% year on year. It was a mixed quarter for the company, with full-year revenue guidance slightly topping analysts’ expectations but a significant miss of analysts’ EPS estimates.

Is Guardant Health a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Guardant Health’s revenue to grow 13% year on year to $190.3 million, slowing from the 30.9% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.59 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Guardant Health has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 5.9% on average.

Looking at Guardant Health’s peers in the healthcare providers & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Quest delivered year-on-year revenue growth of 12.1%, beating analysts’ expectations by 1.3%, and Centene reported revenues up 15.4%, topping estimates by 8.3%. Quest traded up 7.2% following the results while Centene was down 3.3%.

Read our full analysis of Quest’s results here and Centene’s results here.

Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.2% on average over the last month. Guardant Health is up 12.7% during the same time and is heading into earnings with an average analyst price target of $56.24 (compared to the current share price of $48).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.